Guideline for Diagnosis and Management of Aplastic Anemia in Thailand 2020
Keywords:
Aplastic anemia, diagnosis, treatment, guidelinesAbstract
Aplastic anemia is a rare bone marrow disorders due to the failure of bone marrow to form peripheral blood cells. Most of patients have pancytopenia and hypocellular bone marrow mostly secondary to immune-mediated destruction of hematopoietic stem cells. Although aplastic anemia is a rare disease, it is associated with significant morbidity and mortality. Currently, the outcomes of plastic anemia have been improved due to a new treatment such as thrombopoietin receptor agonists as well ass substantial improvement in supportive care, especially antimicrobial agents and transfusion support. The Aplastic Anemia Commitee of Thai Society of Hematology has revised the previous 2011 guidelines using the Guide to Develop Clinical Practice Guidelines which has been endorsed by the Royal College of Physician of Thailand. The draft revised Aplastic Anemia Guidelines were available for public comment before the approval.
Downloads
References
Issaragrisil S, Leaverton PE, Chansung K, Thamprasit T, Porapakham Y, Vannasaeng S, et al. Regional patterns in the incidence of aplastic anemia in Thailand. The Aplastic Anemia Study Group. Am J Hematol. 1999;66:164-8.
Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Leaverton PE, Shapiro S, et al. The epidemiology of aplastic anemia in Thailand. The Aplastic Anemia Study Group. Blood. 2006;107:1299-370.
Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509-19.
Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172:187-207.
Young NS, Bacigalupo A, Marsh J. Aplastic anemia: Pathophysiology and treatment Biol Blood Bone Marrow Transplant. 2010;16:S119-25.
Bacigalupo A, Passweg J. Diagnosis and treatment of acquired aplastic anemia. Hematol Oncol Clin N Am. 2009; 23:159-70.
Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guideline for the diagnosis and management of aplastic anemia. Br J Haematol. 2009;147:43-70.
Shimamura A. Clinical approach to marrow failure. In: Gewirtz AM, Keating A, Thompson AA, editors. American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2009. p. 329-37.
Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica. 2008;93:511-7.
Alter BP, Giri N, Savage SA, Rosenberg Ps. Cancer in dyskeratosis congenita. Blood. 2009;113:6549-6551.
Dokal I, Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. Blood Rev. 2008;22:141-53.
Killick SB, Win N, Marsh JC, Kaye T, Yandle A, Humphries C, et al. Pilot study of HLA alloimmunization after transfusion with pre-storage leucodepleted blood products in aplastic anemia. Br J Haematol. 1997;97:677-84.
Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92:11-8.
Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007;109:4582-5.
Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLAmatched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110:1397-400.
Bacigalupo A, Brand R, Oneto R, Bruno B, Socié G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy. The European group for Blood and Bone Marrow Transplantation experience. Semin Hematol. 2000;37:69-80.
Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic
anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95:1931-4.
Führer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka- Schaub G, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe case predicts better survival. Blood 2005;106: 2102-4.
Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given firstline bone marrow transplantation or immunosuppression treatment in the last decade : a report from The European group for Blood and Bone Marrow Transplantation (EBMT). Haematologica. 2007;91:11-8.
Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. for the German Aplastic Anemia Study Group. Antilymphocyte globulin with or without cyclosporine A: 11 year follow up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236-42.
Narita A, Zhu X, Muramatsu H, Chen X, Guo Y, Yang W, et al. Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia. Br J Haematol. 2019;187:227-37.
Majeed A, Hammadi A, Makki A. Antithymocyte globulin with cyclosporine A and methyl prednisolone in the treatment of aplastic anemia adult patients: Iragi experience. New Engl J Med. 2007;3:24-7.
Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med. 2017;376:1540-50.
Jaime-Pérez JC, Colunga-Pedraza PR, Gómez-Ramírez CD, Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, et al. Danazol as first-line therapy for aplastic anemia. Ann Hematol. 2011;90:523-7.
Townsley DM, Dumitriu B, Liu D, Biancotto A, Weinstein B, Chen C, et al. Danazol Treatment for Telomere Diseases. N Engl J Med. 2016;374:1922-31.
Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgen and erythropoiesis: past and present. J Endocrinol Invest. 2009;32:740-6.
Chuhjo T, Yamazaki H, Omine M, Nakao S. Danazol therapy for aplastic anemia refractory to immunosuppressive therapy. Am J Hematol. 2008;83:387-9.
Zhou Y, Yu R, Shen Y, Zhu N, Lin S, Luo X, et al. The combination of cyclosporine A and androgen in the treatment of chronic aplastic anemia. Zhonghua Xue Ye Xue Za Zhi. 2001;22:186-8.
Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009;94:712-9.
Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11-9.
Lee JW, Lee SE, Jung CW, Park S, Keta H, Park SK, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and longterm treatment phase 2 trial. Lancet Haematol. 2019;6:e562-e572.
AI Rahanwan MM, Giri N, Alter BP. Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita. Int J Hematol. 2006;83:275-76.
Green AM, Kupfer GM. Fanconi anemia. Hematol Oncol Clin North Am. 2009;23:193-214.
Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin North Am. 2009;23:215-31.
Mehta P, Locatelli F, Stary J, Smith F. Bone Marrow Transplantation for Inherited Bone Marrow Failure Syndromes. Pediatr Clin North Am. 2010;57:147-70.
Wagner JE, Eapen M, MacMillan ML, Harris RE, Pasquini R, Boulad F, et al. Unrelated donor bone marrow trans plantation for the treatment of Fanconi anemia. Blood. 2007;109:2256-62.
